Hudson Institute has a focus on the translation of our research to deliver health benefits to the community.
We have a number of opportunities available for collaboration, investment, and licensing, to enable the development and commercialisation of our research and technologies.
Below are examples of technologies developed by Hudson Institute researchers. Contact us if you are interested in these, or if you have a specific area you would like to pursue.
|Exosomes from amniotic epithelial cells for the treatment of disease||Our researchers are developing a unique exosome therapy platform based on amniotic epithelial cells.|
|Novel cancer therapies: blocking the cells that control tumour growth||Researchers at Hudson Institute have identified a mechanism by which cancer cells are able to invade and spread, and are targeting this in the treatment of cancer.|
|Improving survival rates: development of a new diagnostic test for ovarian cancer||Researchers at Hudson Institute are trialling a new test for the detection of ovarian cancer, in the hope of improving survival rates.|
|Improving IVF outcomes: assessing endometrial receptivity||Our researchers are developing a simple blood test to predict the likelihood of a successful IVF embryo transfer, so clinicians and patients can make informed decisions about treatment.|
|Immuno-suppressive therapeutic oligonucleotides||Our researchers have developed a suite of modifications that may be made to antisense oligonucleotides (ASO), for the modulation of immune sensors. This includes the development of a potent cGAS-inhibiting ASO; the group have also identified motifs that can modulate other innate immune sensors, including TLR7 and TLR9. Publication 1. Publication 2.|
For more information on any of our projects, contact Rob Merriel, Chief Commercialisation Officer.